MedTrace Logo

A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

NCT02977533 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-25

No results posted yet for this study

Summary

Primary Objective:

To assess the safety and tolerability of GZ402668 after a single subcutaneous (SC) dose in men and women with progressive multiple sclerosis.

Secondary Objectives:

To assess in men and women with progressive multiple sclerosis:

* The pharmacokinetic (PK) parameters of GZ402668 after a single SC dose.
* The pharmacodynamic (PD) response to GZ402668 after a single SC dose.

Conditions

Interventions

DRUG

GZ402668

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Acyclovir

Pharmaceutical form: tablet Route of administration: oral

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2018-05-16
Completion
2018-05-16

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977533 on ClinicalTrials.gov